Scarica l'app Stockscreener
82.05
3.16%
-2.68
Precedente Chiudi:
$84.73
Aprire:
$85.63
Volume 24 ore:
108.22K
Relative Volume:
0.27
Capitalizzazione di mercato:
$1.20B
Reddito:
$1.30M
Utile/perdita netta:
$-130.19M
Rapporto P/E:
-9.7797
EPS:
-8.3898
Flusso di cassa netto:
$-131.94M
1 W Prestazione:
+0.61%
1M Prestazione:
-13.40%
6M Prestazione:
+7.58%
1 anno Prestazione:
+274.32%
Intervallo 1D:
$80.35
$85.63
Intervallo di 1 settimana:
$77.50
$86.14
Portata 52W:
$20.55
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
82.05 | 1.21B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800 - TradingKey
Inhibrx Biosciences urges expanded research to address unmet needs in head and neck cancer - Traders Union
TradingKey - TradingKey
Inhibrx Biosciences Inc (INBX) Balance Sheet - TradingKey
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX - TradingView
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile? - Sahm
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Biosciences Expands Credit Facility to $500 Million - TipRanks
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
Inhibrx expands credit facility to $500 million with Oxford By Investing.com - Investing.com South Africa
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
Inhibrx Shares Fall After Expanding Loan Agreement to $500M - Moomoo
Inhibrx expands credit facility to $500 million with Oxford - Investing.com
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PR Newswire
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Are you looking for a top momentum pick? Why Inhibrx Biosciences, Inc. (INBX) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Top Cybin (HELP) Competitors 2026 - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Despite Modest Stock GainEarnings Growth Analysis - dars.gov.et
Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights - Benzinga España
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In? - Sahm
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
INBX News | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences urges continued research to address unmet needs in rare cancer treatment - Traders Union
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
INBX Forecast — Price Target — Prediction for 2027 - TradingView
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart - Sahm
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
INBX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline AdvancesEarnings Sentiment Score - dars.gov.et
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):